VolitionRx’s (VNRX) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of VolitionRx (NYSE:VNRX) in a research report released on Friday,Benzinga reports. D. Boral Capital currently has a $3.00 price target on the stock.

A number of other research analysts have also issued reports on the stock. HC Wainwright dropped their price objective on shares of VolitionRx from $2.50 to $1.50 and set a “buy” rating for the company in a report on Monday, November 17th. Maxim Group cut shares of VolitionRx from a “buy” rating to a “hold” rating in a research report on Wednesday, December 3rd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $2.50.

VolitionRx Stock Down 6.1%

Shares of VNRX opened at $0.33 on Friday. The stock has a market cap of $40.89 million, a PE ratio of -0.92 and a beta of 1.23. VolitionRx has a 12-month low of $0.22 and a 12-month high of $0.94. The business has a 50-day simple moving average of $0.31 and a two-hundred day simple moving average of $0.52.

Insider Activity at VolitionRx

In other news, CEO Cameron John Reynolds purchased 110,000 shares of the company’s stock in a transaction dated Tuesday, October 14th. The shares were purchased at an average price of $0.51 per share, for a total transaction of $56,100.00. Following the transaction, the chief executive officer owned 2,534,847 shares of the company’s stock, valued at approximately $1,292,771.97. This trade represents a 4.54% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Guy Archibald Innes acquired 96,153 shares of VolitionRx stock in a transaction dated Tuesday, October 14th. The stock was purchased at an average cost of $0.51 per share, for a total transaction of $49,038.03. Following the completion of the purchase, the director owned 1,062,967 shares in the company, valued at approximately $542,113.17. The trade was a 9.95% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 274,229 shares of company stock worth $136,657 over the last quarter. 10.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On VolitionRx

A number of hedge funds have recently bought and sold shares of VNRX. Silverberg Bernstein Capital Management LLC boosted its position in VolitionRx by 42.8% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company’s stock valued at $153,000 after acquiring an additional 60,209 shares during the last quarter. Blair William & Co. IL acquired a new position in shares of VolitionRx in the 2nd quarter valued at about $30,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of VolitionRx during the 2nd quarter valued at about $52,000. Armistice Capital LLC grew its stake in VolitionRx by 3.5% during the second quarter. Armistice Capital LLC now owns 8,493,074 shares of the company’s stock worth $6,455,000 after purchasing an additional 286,644 shares during the period. Finally, Virtu Financial LLC acquired a new stake in VolitionRx during the third quarter worth approximately $28,000. Institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx NV is a multi-national in vitro diagnostics company focused on the development and commercialization of novel blood-based tests for the detection and monitoring of cancer and other diseases. The company’s proprietary Nucleosomics® technology leverages epigenetic and structural changes in nucleosomes—fragments of DNA wrapped around histone proteins—to identify disease-specific biomarkers in blood samples. VolitionRx’s primary goal is to offer simple, minimally invasive tests that facilitate early detection and improve patient outcomes.

VolitionRx’s product pipeline centers on the Nu.Q® family of immunoassays, which are designed to measure concentrations and modifications of circulating nucleosomes.